Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2009 Target Snapshot

Glutamate receptor 1 · SINGLE PROTEIN · Homo sapiens

381Compounds
81Assays
2Approved Drugs
462.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-15

Glutamate receptor 1 shows clinical signal disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P42261. Start with amyotrophic lateral sclerosis, then reuse UniProt P42261 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with amyotrophic lateral sclerosis, then reuse UniProt P42261 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-15 1 linked drug
Open source guide
Disease program
amyotrophic lateral sclerosis

Glutamate receptor 1 shows clinical signal disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with amyotrophic lateral sclerosis because it currently carries clinical signal support. Linked drugs include TALAMPANEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate receptor 1 as ChEMBL target CHEMBL2009, mapped to UniProt P42261. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-15
ChEMBL target ID
CHEMBL2009
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-15
www.ebi.ac.uk
UniProt accession
P42261
Glutamate receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-15
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-15
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate receptor 1 is the right protein anchor across sources, using UniProt P42261 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why amyotrophic lateral sclerosis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor 1
UniProt AccessionP42261
Component TypeProtein
Sequence Length906 aa

Glutamate receptor 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Glutamate receptor 1, mapped to UniProt P42261. Sequence length is 906 aa.

Mapped IDP42261
Review nameGlutamate receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Glutamate receptor 1 shows clinical signal disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
amyotrophic lateral sclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
anaplastic astrocytoma
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
anaplastic oligodendroglioma
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
Central Nervous System Neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with amyotrophic lateral sclerosis because it currently carries clinical signal support. Linked drugs include TALAMPANEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseamyotrophic lateral sclerosis
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC50307.0
KI82.0
EC5073.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL6019202 10.3 IC50 0.05 Preclinical
CHEMBL5767381 10.22 IC50 0.06 Preclinical
CHEMBL5922169 10.22 IC50 0.06 Preclinical
CHEMBL6041259 10.22 IC50 0.06 Preclinical
CHEMBL4522808 10.1 IC50 0.08 Preclinical
CHEMBL5881588 10.1 IC50 0.08 Preclinical
CHEMBL5942693 10.1 IC50 0.08 Preclinical
CHEMBL5769276 10.0 IC50 0.1 Preclinical
CHEMBL5801723 9.89 IC50 0.13 Preclinical
CHEMBL5849167 9.89 IC50 0.13 Preclinical
Distribution

pChEMBL Value Distribution

35
5.0
16
5.5
43
6.0
57
6.5
38
7.0
41
7.5
44
8.0
32
8.5
42
9.0
19
9.5
pChEMBL
Approved Drugs

Approved Drugs

PERAMPANEL
CHEMBL1214124
Approved 2012
CYCLOTHIAZIDE
CHEMBL61593
Approved 1982
Assay Landscape

Assay Landscape

81
Total Assays
327
Tested Compounds
2
Assay Types
Binding — 49 assays, 327 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 37 322 7.4
single protein format 11 5 5.2
assay format 1 0
Functional — 32 assays, 16 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 31 15 5.0
assay format 1 1 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine